Immunotherapy of skin diseases caused by the human papillomavirus

References

• Trus BL, Roden RB, Greenstone HL. Novel structural features of bovine papilloma virus capsid revealed by a three-dimensional reconstruction to 9 Å resolution. Nature Struct. Biol. 4, 413–420 (1997).
   PubMedGoogle Scholar
• Schiller JT, Okun MM. Papillomavirus vaccines: current status and future prospects. Adv. Dermatol. 11, 355–381 (1996).
   PubMedGoogle Scholar
• Ramoz N, Rueda LA, Bouadjar B et al. A susceptibility locus for epidermodysplasia verruciformis, an abnormal predisposition to infection with the oncogenic human papillomavirus Type 5, maps to chromosome 17qter in a region containing a psoriasis locus. J. Invest. Dermatol. 112, 259–263 (1999).
   PubMed Web of Science ®Google Scholar
• Ishiji T, Ibe M, Kawase M et al. Patients with epidermodysplasia verruciformis show no response to contact immunotherapy. Dermatology 202(1), 76–77 (2001).
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364(9447), 1757–1765 (2004).
   PubMed Web of Science ®Google Scholar
• Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus Type 16 vaccine. N. Engl. J. Med. 347(21), 1645–1651 (2002).
   PubMed Web of Science ®Google Scholar
• Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nature Rev. Immunol. 4(1), 46–54 (2004).
   PubMed Web of Science ®Google Scholar
• Gibbs S, Harvey I, Sterling J, Stark R. Local treatments for cutaneous warts: systematic review. BMJ 325(7362), 461 (2002).
   PubMed Web of Science ®Google Scholar
• Micali G, Dall’Oglio F, Nasca MR, Tedeschi A. Management of cutaneous warts: an evidence-based approach. Am. J. Clin. Dermatol. 5(5), 311–317 (2004).
   PubMed Web of Science ®Google Scholar
• Brodell RT, Johnson SM (Eds). Warts: Diagnosis and Management: An Evidence-based Approach. Brodel RT, Johnson SM (Eds). Martin Dunitz, London, UK (2003).
   Google Scholar
• Hallmo P, Naess O. Laryngeal papillomatosis with human papillomavirus DNA contracted by a laser surgeon. Eur. Arch. Otorhinolaryngol. 248(7), 425–427 (1991).
   PubMed Web of Science ®Google Scholar
• Dall’ Oglio F, Nasca MR, D’Agata O, Micali G. Adult and paediatric contact immunotherapy with squaric acid dibutylester (SADBE) for recurrent, multiple, resistant, mucocutaneous anogenital warts. Sex. Transm. Infect. 78(4), 309–310 (2002).
   PubMedGoogle Scholar
• Gibbs S. Topical immunotherapy with contact sensitizers for viral warts. Br. J. Dermatol. 146(4), 705 (2002).
   PubMedGoogle Scholar
• Silverberg NB, Lim JK, Paller AS et al. Squaric acid immunotherapy for warts in children. J. Am. Acad. Dermatol. 42(5 Pt 1), 803–808 (2000).
   PubMed Web of Science ®Google Scholar
• Micali G, Nasca MR, Tedeschi A, Dall’Oglio F, Pulvirenti N. Use of squaric acid dibutylester (SADBE) for cutaneous warts in children. Pediatr. Dermatol. 17(4), 315–318 (2000).
   PubMed Web of Science ®Google Scholar
• Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J. Am. Acad. Dermatol. 43(1 Pt 2), S6–S11 (2000).
   PubMed Web of Science ®Google Scholar
• Edwards L, Ferenczy A, Eron L et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch. Dermatol. 134, 25–30 (1998).
   PubMed Web of Science ®Google Scholar
• Petrow W, Gerdsen R, Uerlich M et al. Successful topical immunotherapy of bowenoid papulosis with imiquimod. Br. J. Dermatol. 145(6), 1022–1023 (2001).
   PubMed Web of Science ®Google Scholar
• Micali G, Dall’Oglio F, Nasca MR. An open label evaluation of the efficacy of imiquimod 5% cream in the treatment of recalcitrant subungual and periungual cutaneous warts. J. Dermatolog. Treat. 14(4), 233–236 (2003).
   PubMedGoogle Scholar
• Parsad D, Pandhi R, Juneja A et al. Cimetidine and levamisole versus cimetidine alone for recalcitrant warts in children. Pediatr. Dermatol. 18(4), 349–352 (2001).
   PubMedGoogle Scholar
• Horn TD, Johnson SM, Helm RM, Roberson PK. Intralesional immunotherapy of warts with mumps, Candida and trichophyton skin test antigens: a single-blinded, randomized and controlled trial. Arch. Dermatol. 141(5), 589–594 (2005).
   PubMed Web of Science ®Google Scholar
• King M, Johnson SM, Horn TD. Intralesional immunotherapy for genital warts. Arch. Dermatol. 141(12), 1606–1607 (2005).
   PubMed Web of Science ®Google Scholar
• Perman M, Sterling JB, Gaspari A. The painful purple digit: an alarming complication of Candida albicans antigen treatment of recalcitrant warts. Dermatitis 16(1), 38–40 (2005).
   PubMed Web of Science ®Google Scholar
• van der Steen P, van de Kerkhof P, der Kinderen D et al. Clinical and immunohistochemical responses of plantar warts to topical immunotherapy with diphenylcyclopropenone. J. Dermatol. 18(6), 330–333 (1991).
   PubMedGoogle Scholar